Table 3 Relationship between UBE2C expression and the clinico-pathological features of BRCA
Clinico-pathological parameters | UBE2C | χ2 | P value | |
|---|---|---|---|---|
Negative (−) % | Positive (+ to +++) % | |||
Age (year) | Â | Â | 0.412 | 0.521 |
 ≤ 50 | 30 (27.3) | 80 (72.7) |  |  |
 > 50 | 31 (31.3) | 68 (68.7) |  |  |
Histological grade | Â | Â | 12.333 | <0.001 |
 I + II | 45 (39.1) | 70 (60.9) |  |  |
 III | 16 (17.0) | 78 (83.0) |  |  |
Pathological stage (PTNM) | Â | Â | 8.209 | 0.005 |
 I + II | 51 (35.2) | 94 (64.8) |  |  |
 III + IV | 10 (15.6) | 54 (84.4) |  |  |
Tumor size (cm) | Â | Â | 4.367 | 0.042 |
 ≤ 5 | 59 (31.4) | 129 (68.6) |  |  |
 > 5 | 2 (9.5) | 19 (90.5) |  |  |
Lymph node metastasis (N) | Â | Â | 4.978 | 0.026 |
 No (N0) | 38 (35.9) | 66 (64.1) |  |  |
 Yes (N1–N3) | 23 (21.9) | 82 (78.1) |  |  |
Distant metastasis (M) | Â | Â | 0.209 | 1.000 |
 M0 | 60 (29.4) | 144 (70.6) |  |  |
 M1 | 1 (20.0) | 4 (80.0) |  |  |
Clinical stage | Â | Â | 8.209 | 0.004 |
 I + II | 51 (35.2) | 94 (69.4) |  |  |
 III + IV | 10 (15.6) | 54 (84.4) |  |  |